By Helgi Library - April 2, 2020
Bayer Czech Republic's total assets reached CZK 1,165 mil at the end of 2017, down 3.71% compared to the previous year. ...
By Helgi Library - April 2, 2020
Bayer Czech Republic's total assets reached CZK 1,165 mil at the end of 2017, down 3.71% compared to the previous year. ...
| Profit Statement | 2015 | 2016 | 2017 | |
| Sales | CZK mil | 4,277 | 4,326 | 4,180 |
| Gross Profit | CZK mil | 592 | 621 | 487 |
| EBITDA | CZK mil | 168 | 233 | 158 |
| EBIT | CZK mil | 164 | 228 | 151 |
| Financing Cost | CZK mil | 1.58 | 3.82 | 4.04 |
| Pre-Tax Profit | CZK mil | 162 | 224 | 147 |
| Net Profit | CZK mil | 123 | 175 | 106 |
| Dividends | CZK mil | 60.0 | 50.0 | ... |
| Balance Sheet | 2015 | 2016 | 2017 | |
| Total Assets | CZK mil | 830 | 1,210 | 1,165 |
| Non-Current Assets | CZK mil | 16.1 | 16.1 | 13.6 |
| Current Assets | CZK mil | 810 | 1,190 | 1,145 |
| Working Capital | CZK mil | 463 | 1,016 | 984 |
| Shareholders' Equity | CZK mil | 246 | 361 | 417 |
| Liabilities | CZK mil | 584 | 849 | 748 |
| Total Debt | CZK mil | 151 | 467 | 404 |
| Net Debt | CZK mil | 150 | 461 | 393 |
| Ratios | 2015 | 2016 | 2017 | |
| ROE | % | 50.6 | 57.6 | 27.2 |
| ROCE | % | 29.0 | 23.1 | 10.4 |
| Gross Margin | % | 13.8 | 14.3 | 11.6 |
| EBITDA Margin | % | 3.93 | 5.38 | 3.77 |
| EBIT Margin | % | 3.83 | 5.27 | 3.62 |
| Net Margin | % | 2.89 | 4.04 | 2.53 |
| Net Debt/EBITDA | 0.890 | 1.98 | 2.49 | |
| Net Debt/Equity | % | 60.8 | 128 | 94.4 |
| Cost of Financing | % | 1.76 | 1.24 | 0.929 |
| Cash Flow | 2015 | 2016 | 2017 | |
| Total Cash From Operations | CZK mil | ... | -247 | 122 |
| Total Cash From Investing | CZK mil | ... | -4.84 | -3.60 |
| Total Cash From Financing | CZK mil | ... | 256 | -113 |
| Net Change In Cash | CZK mil | ... | 4.64 | 5.25 |
| Cash Conversion Cycle | days | 40.3 | 93.0 | 91.9 |
| Cash Earnings | CZK mil | 128 | 180 | 112 |
| Free Cash Flow | CZK mil | ... | -251 | 118 |
Get all company financials in excel:
| summary | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| income statement | ||||||||||||||||
| Sales | CZK mil | 3,344 | 3,245 | 3,438 | 4,054 | 4,277 | ||||||||||
| Gross Profit | CZK mil | 1.69 | 372 | 451 | 499 | 592 | ||||||||||
| EBIT | CZK mil | 160 | 104 | 128 | 139 | 164 | ||||||||||
| Net Profit | CZK mil | 166 | 83.4 | 96.2 | 107 | 123 | ||||||||||
| ROE | % | 34.8 | 22.3 | 33.5 | 40.5 | 50.6 | ||||||||||
| EBIT Margin | % | 4.77 | 3.22 | 3.72 | 3.43 | 3.83 | ||||||||||
| Net Margin | % | 4.96 | 2.57 | 2.80 | 2.64 | 2.89 | ||||||||||
| Employees | 184 | 170 | 178 | 181 | 187 | |||||||||||
| balance sheet | ||||||||||||||||
| Total Assets | CZK mil | 774 | 572 | 698 | 682 | 830 | ||||||||||
| Non-Current Assets | CZK mil | 70.6 | 30.5 | 17.1 | 15.2 | 16.1 | ||||||||||
| Current Assets | CZK mil | 698 | 539 | 678 | 662 | 810 | ||||||||||
| Shareholders' Equity | CZK mil | 460 | 289 | 286 | 243 | 246 | ||||||||||
| Liabilities | CZK mil | 314 | 283 | 413 | 440 | 584 | ||||||||||
| Non-Current Liabilities | CZK mil | 7.97 | 3.22 | 0 | 0 | 0 | ||||||||||
| Current Liabilities | CZK mil | 306 | 280 | 410 | 426 | 522 | ||||||||||
| Net Debt/EBITDA | -0.298 | -0.098 | 0.140 | 0.150 | 0.890 | |||||||||||
| Net Debt/Equity | % | -10.9 | -3.80 | 6.64 | 8.88 | 60.8 | ||||||||||
| Cost of Financing | % | ... | ... | ... | ... | ... | ... | ... | ... | 11.0 | 6.28 | 1.76 | ||||
| cash flow | ||||||||||||||||
| Total Cash From Operations | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Total Cash From Investing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Total Cash From Financing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Net Change In Cash | CZK mil | ... | ... | ... | ... | ... | ... | ... |
| income statement | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| income statement | ||||||||||||||||
| Sales | CZK mil | 3,344 | 3,245 | 3,438 | 4,054 | 4,277 | ||||||||||
| Cost of Goods & Services | CZK mil | 3,342 | 2,873 | 2,987 | 3,555 | 3,684 | ||||||||||
| Gross Profit | CZK mil | 1.69 | 372 | 451 | 499 | 592 | ||||||||||
| Staff Cost | CZK mil | 250 | 243 | 277 | 297 | 324 | ||||||||||
| Other Cost | CZK mil | -416 | 17.0 | 38.3 | 59.0 | 100 | ||||||||||
| EBITDA | CZK mil | 168 | 112 | 135 | 143 | 168 | ||||||||||
| Depreciation | CZK mil | 7.96 | 7.87 | 7.63 | 4.06 | 4.42 | ||||||||||
| EBIT | CZK mil | 160 | 104 | 128 | 139 | 164 | ||||||||||
| Financing Cost | CZK mil | -35.4 | 2.33 | 4.94 | 3.72 | 1.58 | ||||||||||
| Extraordinary Cost | CZK mil | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Pre-Tax Profit | CZK mil | 195 | 102 | 123 | 135 | 162 | ||||||||||
| Tax | CZK mil | 29.1 | 18.6 | 26.7 | 28.3 | 38.7 | ||||||||||
| Minorities | CZK mil | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Net Profit | CZK mil | 166 | 83.4 | 96.2 | 107 | 123 | ||||||||||
| Dividends | CZK mil | 0 | 100 | 150 | 120 | 60.0 | ... | |||||||||
| growth rates | ||||||||||||||||
| Total Revenue Growth | % | ... | -2.02 | -2.94 | 5.93 | 17.9 | 5.49 | |||||||||
| Operating Cost Growth | % | ... | -158 | -257 | 21.4 | 12.8 | 19.2 | |||||||||
| EBITDA Growth | % | ... | -0.531 | -33.0 | 20.7 | 5.62 | 17.5 | |||||||||
| EBIT Growth | % | ... | 6.82 | -34.6 | 22.5 | 8.75 | 17.7 | |||||||||
| Pre-Tax Profit Growth | % | ... | 27.9 | -47.7 | 20.5 | 10.1 | 19.8 | |||||||||
| Net Profit Growth | % | ... | 39.4 | -49.7 | 15.3 | 11.2 | 15.4 | |||||||||
| ratios | ||||||||||||||||
| ROE | % | 34.8 | 22.3 | 33.5 | 40.5 | 50.6 | ||||||||||
| ROCE | % | ... | 170 | 27.1 | 26.9 | 28.9 | 29.0 | |||||||||
| Gross Margin | % | 0.050 | 11.5 | 13.1 | 12.3 | 13.8 | ||||||||||
| EBITDA Margin | % | 5.01 | 3.46 | 3.94 | 3.53 | 3.93 | ||||||||||
| EBIT Margin | % | 4.77 | 3.22 | 3.72 | 3.43 | 3.83 | ||||||||||
| Net Margin | % | 4.96 | 2.57 | 2.80 | 2.64 | 2.89 | ||||||||||
| Payout Ratio | % | 0 | 120 | 156 | 112 | 48.6 | ... | |||||||||
| Cost of Financing | % | ... | ... | ... | ... | ... | ... | ... | ... | 11.0 | 6.28 | 1.76 | ||||
| Net Debt/EBITDA | -0.298 | -0.098 | 0.140 | 0.150 | 0.890 |
| balance sheet | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| balance sheet | ||||||||||||||||
| Non-Current Assets | CZK mil | 70.6 | 30.5 | 17.1 | 15.2 | 16.1 | ||||||||||
| Property, Plant & Equipment | CZK mil | 24.1 | 20.0 | 16.7 | 14.7 | 15.1 | ||||||||||
| Intangible Assets | CZK mil | 3.24 | 1.05 | 0.395 | 0.504 | 1.01 | ||||||||||
| Current Assets | CZK mil | 698 | 539 | 678 | 662 | 810 | ||||||||||
| Inventories | CZK mil | 145 | 193 | 185 | 230 | 263 | ||||||||||
| Receivables | CZK mil | 264 | 268 | 356 | 357 | 403 | ||||||||||
| Cash & Cash Equivalents | CZK mil | 50.0 | 11.0 | 71.2 | 6.99 | 0.936 | ||||||||||
| Total Assets | CZK mil | 774 | 572 | 698 | 682 | 830 | ||||||||||
| Shareholders' Equity | CZK mil | 460 | 289 | 286 | 243 | 246 | ||||||||||
| Of Which Minority Interest | CZK mil | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Liabilities | CZK mil | 314 | 283 | 413 | 440 | 584 | ||||||||||
| Non-Current Liabilities | CZK mil | 7.97 | 3.22 | 0 | 0 | 0 | ||||||||||
| Long-Term Debt | CZK mil | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Deferred Tax Liabilities | CZK mil | 0 | 0 | 0 | 0 | 0 | ||||||||||
| Current Liabilities | CZK mil | 306 | 280 | 410 | 426 | 522 | ||||||||||
| Short-Term Debt | CZK mil | 0 | 0 | 90.1 | 28.5 | 151 | ||||||||||
| Trade Payables | CZK mil | 210 | 146 | 188 | 230 | 204 | ||||||||||
| Provisions | CZK mil | 3.92 | 0 | 0 | 12.1 | 61.9 | ||||||||||
| Equity And Liabilities | CZK mil | 774 | 572 | 698 | 682 | 830 | ||||||||||
| growth rates | ||||||||||||||||
| Total Asset Growth | % | ... | -41.7 | -26.0 | 22.0 | -2.28 | 21.7 | |||||||||
| Shareholders' Equity Growth | % | ... | -6.69 | -37.1 | -1.31 | -15.1 | 1.44 | |||||||||
| Net Debt Growth | % | ... | -71.1 | -78.0 | -272 | 13.5 | 595 | |||||||||
| Total Debt Growth | % | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | -68.3 | 428 | |||
| ratios | ||||||||||||||||
| Total Debt | CZK mil | 0 | 0 | 90.1 | 28.5 | 151 | ||||||||||
| Net Debt | CZK mil | -50.0 | -11.0 | 19.0 | 21.5 | 150 | ||||||||||
| Working Capital | CZK mil | 199 | 315 | 353 | 356 | 463 | ||||||||||
| Capital Employed | CZK mil | 270 | 345 | 371 | 371 | 479 | ||||||||||
| Net Debt/Equity | % | -10.9 | -3.80 | 6.64 | 8.88 | 60.8 | ||||||||||
| Cost of Financing | % | ... | ... | ... | ... | ... | ... | ... | ... | 11.0 | 6.28 | 1.76 |
| cash flow | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| cash flow | ||||||||||||||||
| Net Profit | CZK mil | 166 | 83.4 | 96.2 | 107 | 123 | ||||||||||
| Depreciation | CZK mil | 7.96 | 7.87 | 7.63 | 4.06 | 4.42 | ||||||||||
| Non-Cash Items | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Change in Working Capital | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Total Cash From Operations | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Capital Expenditures | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Other Investments | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Total Cash From Investing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Dividends Paid | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Issuance Of Shares | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ... | ||
| Issuance Of Debt | CZK mil | ... | ... | ... | ... | ... | ... | ... | ... | |||||||
| Total Cash From Financing | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Net Change In Cash | CZK mil | ... | ... | ... | ... | ... | ... | ... | ||||||||
| ratios | ||||||||||||||||
| Days Sales Outstanding | days | 28.8 | 30.2 | 37.8 | 32.1 | 34.4 | ||||||||||
| Days Sales Of Inventory | days | 15.8 | 24.6 | 22.6 | 23.6 | 26.1 | ||||||||||
| Days Payable Outstanding | days | 22.9 | 18.6 | 23.0 | 23.7 | 20.2 | ||||||||||
| Cash Conversion Cycle | days | 21.7 | 36.1 | 37.5 | 32.0 | 40.3 | ||||||||||
| Cash Earnings | CZK mil | 174 | 91.3 | 104 | 111 | 128 | ||||||||||
| Free Cash Flow | CZK mil | ... | ... | ... | ... | ... | ... | ... |
| other data | Unit | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 |
| other data | ||||||||||||||||
| ROA | % | 15.8 | 12.4 | 15.1 | 15.5 | 16.3 | ||||||||||
| Gross Margin | % | 0.050 | 11.5 | 13.1 | 12.3 | 13.8 | ||||||||||
| Employees | 184 | 170 | 178 | 181 | 187 | |||||||||||
| Cost Per Employee | USD per month | 6,399 | 6,086 | 6,633 | 6,393 | 6,044 | ||||||||||
| Cost Per Employee (Local Currency) | CZK per month | 113,170 | 119,036 | 129,773 | 136,628 | 144,259 | ||||||||||
| Staff Cost (As % Of Total Cost) | % | 7.85 | 7.73 | 8.37 | 7.58 | 7.87 | ||||||||||
| Effective Tax Rate | % | 14.9 | 18.2 | 21.7 | 20.9 | 23.8 | ||||||||||
| Domestic Sales | CZK mil | 2,475 | 2,444 | 2,503 | 3,017 | 3,242 | ||||||||||
| Capital Expenditures (As % of Sales) | % | ... | ... | ... | ... | ... | ... | ... | ||||||||
| Revenues From Abroad | CZK mil | 17.0 | 24.0 | 23.2 | 1,037 | 1,034 | ||||||||||
| Revenues From Abroad (As % Of Total) | % | 0.508 | 0.740 | 0.673 | 25.6 | 24.2 |
Get all company financials in excel:
Bayer, s.r.o. (or Bayer Czech Republic in our case) is a Czech Republic-based subsidiary of Bayer AG, the German chemical and pharmaceutical company founded in Barmen, Germany in 1863. It is headquartered in Leverkusen, North Rhine-Westphalia, Germany and well known for its original brand of aspirin. The Company is now a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. In fiscal year 2013, Bayer employed 113,200 people and had sales of EUR 40.2 bil.
Bayer Czech Republic has been growing its sales by a year on average in the last 5 years. EBITDA has grown on average by 7.04% a year during that time to total of CZK 158 mil in 2017, or 3.77% of sales. That’s compared to 4.11% average margin seen in last five years.
The company netted CZK 106 mil in 2017 implying ROE of 27.2% and ROCE of 10.4%. Again, the average figures were 41.9% and 23.7%, respectively when looking at the previous 5 years.
Bayer Czech Republic’s net debt amounted to CZK 393 mil at the end of 2017, or 94.4% of equity. When compared to EBITDA, net debt was 2.49x, up when compared to average of 1.13x seen in the last 5 years.
Helgi Library 
